These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 17192883

  • 1. The current status of breast cancer chemoprevention: a star is born.
    Morrow M, Jordan VC.
    J Surg Oncol; 2007 Jan 01; 95(1):4-5. PubMed ID: 17192883
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chemoprevention of breast cancer: recommendations and rationale.
    Am Fam Physician; 2003 Mar 15; 67(6):1309-14. PubMed ID: 12674459
    [No Abstract] [Full Text] [Related]

  • 5. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO, U.S. Preventive Services Task Force.
    Am J Nurs; 2003 May 15; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract] [Full Text] [Related]

  • 6. Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.
    Jordan VC.
    Eur J Cancer; 2006 Nov 15; 42(17):2909-13. PubMed ID: 17064889
    [Abstract] [Full Text] [Related]

  • 7. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.
    Fabian C.
    Cancer Epidemiol Biomarkers Prev; 2007 Nov 15; 16(11):2210-2. PubMed ID: 18006909
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.
    Vastag B.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):733-5. PubMed ID: 16757696
    [No Abstract] [Full Text] [Related]

  • 11. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    McKay A, Latosinsky S, Martin W.
    Cancer; 2005 Jan 01; 103(1):209-10. PubMed ID: 15540238
    [No Abstract] [Full Text] [Related]

  • 12. Women's decision making about whether or not to use breast cancer chemoprevention.
    Altschuler A, Somkin CP.
    Women Health; 2005 Jan 01; 41(2):81-95. PubMed ID: 16219589
    [Abstract] [Full Text] [Related]

  • 13. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
    Bevers TB.
    J Natl Compr Canc Netw; 2007 Sep 01; 5(8):719-24. PubMed ID: 17927929
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tamoxifen (TAM): the dispute goes on.
    Grilli S.
    Ann Ist Super Sanita; 2006 Sep 01; 42(2):170-3. PubMed ID: 17033137
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tamoxifen: an enduring star.
    Veronesi U, Maisonneuve P, Decensi A.
    J Natl Cancer Inst; 2007 Feb 21; 99(4):258-60. PubMed ID: 17312297
    [No Abstract] [Full Text] [Related]

  • 19. Tamoxifen and breast cancer prevention: what should you tell your patients?
    Goel V.
    CMAJ; 1998 Jun 16; 158(12):1615-7. PubMed ID: 9645176
    [No Abstract] [Full Text] [Related]

  • 20. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
    Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M.
    Cancer; 2004 May 01; 100(9):1800-6. PubMed ID: 15112259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.